A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects

NCT03905850 | Completed Phase 1

• 3 other identifiers: NN8640-44912018-003670-27U1111-1220-5197
• Study Type: interventional
• Target: 33
• Locations: 1 country
• Sites: 1

Brief Summary

This study will compare two strengths of the new long-acting growth hormone somapacitan. The aim of this study is to test if both strengths are taken up in the blood in the same way. During three separate dosing visits participants will get a total of 3 injections of the study medicine. Somapacitan is not yet approved and therefore cannot be prescribed by a doctor outside of this study. The study duration is between 10 and 15 weeks. Participants will have 17 visits with the study doctor. Three visits will each comprise 6 in-house days with overnight stays. In total, at least 15 overnight stays at the clinic. There will be blood samplings during the study. Participants must come to the clinic regularly for these blood samplings. People who have already received growth hormones in the past or who are growth hormone deficient cannot be in the study. People cannot be in the study if the study doctor thinks that there are risks for their health. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.

Conditions

Healthy Volunteers; Growth Hormone Deficiency

Outcome Measures

Primary Outcomes (2)

• Area under the somapacitan serum concentration time curve from time 0 to the time of the last quantifiable concentration after dosing

  ng\*h/mL

  0 to 504 hours after trial product administration

• Maximum serum concentration of somapacitan

  ng/mL

  0 to 504 hours after trial product administration

Secondary Outcomes (7)

• Area under the somapacitan serum concentration time curve from time 0 to 168 hours after dosing

  0 to 168 hours after trial product administration

• Area under the somapacitan serum concentration time curve from time 0 to infinity

  0 to 504 hours after trial product administration

• Time to maximum serum concentration of somapacitan

  0 to 504 hours after trial product administration

• Terminal half-life of somapacitan

  0 to 504 hours after trial product administration

• Area under the insulin-like growth factor I (IGF-I) serum concentration time curve from time 0 to 168 hours after dosing

  0 to 168 hours after trial product administration

Study Arms (3)

Somapacitan 5/10/10 mg

EXPERIMENTAL

One dose of somapacitan 5 mg/1.5 ml followed by two doses of somapacitan 10 mg/1.5 ml. Each dose will be followed by a 3 week observation period.

Drug: somapacitan

Somapacitan 10/5/10 mg

EXPERIMENTAL

One dose of somapacitan 10 mg/1.5 ml followed by a 5 mg/1.5 ml dose followed by a 10 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.

Drug: somapacitan

Somapacitan 10/10/5 mg

EXPERIMENTAL

Two doses of 10 mg/1.5 ml somapacitan followed by a 5 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.

Drug: somapacitan

Interventions

somapacitan DRUG

5 mg/1.5 ml and 10 mg/1.5 ml doses administered s.c. (subcutaneously, under the skin)

Somapacitan 10/10/5 mg; Somapacitan 10/5/10 mg; Somapacitan 5/10/10 mg

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female, aged 18-45 years (both inclusive) at the time of signing informed consent.
• Body mass index (BMI) between 18.5 and 24.9 kg/m\^2 (both inclusive).
• Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.

You may not qualify if:

• Participation in any clinical trial of an approved or non-approved investigational medicinal product within 45 days or 5 times the half-life of the previous investigational medicinal product, whichever is longer, before screening.
• Body weight above 100.0 kg
• Subject with any known history of growth hormone deficiency as declared by the subject.
• Subject who is non-naïve to growth hormone treatment as declared by the subject.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

Novo Nordisk Investigational Site

Neuss, 41460, Germany

Location

Related Publications (1)

• Dombernowsky SL, Damholt BB, Hojby Rasmussen M, Svaerke C, Kildemoes RJ. Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clin Pharmacokinet. 2024 Jul;63(7):1015-1024. doi: 10.1007/s40262-024-01395-y. Epub 2024 Jul 5.

  PMID: 38969919 DERIVED

MeSH Terms

Conditions

Dwarfism, Pituitary

Interventions

somapacitan

Condition Hierarchy (Ancestors)

Dwarfism; Bone Diseases, Developmental; Bone Diseases; Musculoskeletal Diseases; Bone Diseases, Endocrine; Hypopituitarism; Pituitary Diseases; Hypothalamic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Endocrine System Diseases

Study Officials

• Clinical Reporting Anchor and Disclosure (1452)

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Sponsor staff involved in the clinical trial is masked according to company standard procedures.
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 3, 2019
• First Posted: April 5, 2019
• Study Start: March 29, 2019
• Primary Completion: July 15, 2019
• Study Completion: July 15, 2019
• Last Updated: August 6, 2019

Record last verified: 2019-08

Data Sharing

• IPD Sharing: Will share

Locations

DE (1)